Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy.
A cross-sectional study of impaired glucose metabolism was carried out in 48 beta-thalassemic patients receiving hypertransfusions. An oral glucose tolerance test (OGTT) was performed using the method and criteria of the American Diabetes Association (ADA). Diabetes mellitus was diagnosed in two patients, and impaired glucose tolerance was found in four patients, giving a prevalence of impaired glucose metabolism of 12.5% in our patient population. The significant clinical characteristics associated with the diagnosis of impaired glucose metabolism were wasting (-2.15/-0.86 SDS, p = 0.025), stunting (-2.69/-1.22 SDS, p = 0.03), higher ferritin levels (8679/4710 microg/L, p = 0.005), splenectomy (50/9.5%, p = 0.012), and lower area under curve (AUC) of insulin secretion after OGTT (40.0/77.7, p = 0.002). The significant decrease of AUC insulin in thalassemic patients with an impaired glucose tolerance test suggests that the pathogenesis may originate from pancreatic beta-cell damage rather than from insulin resistance. In conclusion, the prevalence of impaired glucose tolerance in our population of thalassemic patients receiving hypertransfusions with suboptimal iron chelating therapy was 12.5%. The clinical characteristics of thalassemic patients who developed impaired glucose tolerance were wasting, stunting, higher ferritin levels, splenectomy, and lower AUC insulin.
Jaruratanasirikul
Somchit
S
Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand. somchit.j@psu.ac.th
Chareonmuang
Rarong
R
Wongcharnchailert
Malai
M
Laosombat
Vichai
V
Sangsupavanich
Pasuree
P
Leetanaporn
Kalaya
K
D000293:Adolescent; D019540:Area Under Curve; D015913:Chelation Therapy; D002648:Child; D003430:Cross-Sectional Studies; D003676:Deferoxamine / Q000008:administration & dosage*; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005293:Ferritins / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism*
D007502:Iron Chelating Agents; D005293:Ferritins; D005947:Glucose; D003676:Deferoxamine